2025
427. Underlying Medical Conditions and Vaccination Status among U.S. Children Aged ≤17 Years Hospitalized for COVID-19 in COVID-19-Associated Hospitalization Surveillance Network (COVID-NET), January–December 2023
Free R, Patel K, Sachdev D, Alden N, Meek J, Ryan P, Falkowski A, D’Heilly P, Smelser C, Engesser K, Bushey S, Moran N, Sutton M, Talbot H, Swain A, Campbell A, Havers F, Openo K. 427. Underlying Medical Conditions and Vaccination Status among U.S. Children Aged ≤17 Years Hospitalized for COVID-19 in COVID-19-Associated Hospitalization Surveillance Network (COVID-NET), January–December 2023. Open Forum Infectious Diseases 2025, 12: ofae631.141. PMCID: PMC11777352, DOI: 10.1093/ofid/ofae631.141.Peer-Reviewed Original ResearchCOVID-19-Associated Hospitalization Surveillance NetworkAge-eligible childrenChildren aged 6Medical conditionsCOVID-19 hospitalizationVaccine doseAcute care hospitalsAged 6Random sample of childrenPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsVaccination statusAssessed patient ageSample of childrenNeurological disordersMaster of ScienceSARS-CoV-2 infectionActive surveillance systemCare hospitalProbability of selectionPediatric COVID-19 vaccineCOVID-19U.S. childrenPatient ageMedical records
2024
Development of a prediction model for 30-day COVID-19 hospitalization and death in a national cohort of Veterans Health Administration patients–March 2022—April 2023
Bui D, Bajema K, Huang Y, Yan L, Li Y, Rajeevan N, Berry K, Rowneki M, Argraves S, Hynes D, Huang G, Aslan M, Ioannou G. Development of a prediction model for 30-day COVID-19 hospitalization and death in a national cohort of Veterans Health Administration patients–March 2022—April 2023. PLOS ONE 2024, 19: e0307235. PMID: 39365775, PMCID: PMC11451987, DOI: 10.1371/journal.pone.0307235.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 hospitalizationArea under the receiver operating characteristic curveComprehensive electronic health recordNational cohortElectronic health recordsAll-cause mortalityNational cohort of patientsFull modelHealth recordsHealth AdministrationReceipt of COVID-19 vaccineMortality riskEpidemiology of COVID-19COVID-19High-risk patientsBrier scoreCohort of patientsAnti-SARS-CoV-2 treatmentCOVID-19 vaccineReceiver operating characteristic curveCalibration interceptHospitalAntiviral treatmentAvailability of effective vaccinesIn-Hospital Delirium and Disability and Cognitive Impairment After COVID-19 Hospitalization
Kaushik R, McAvay G, Murphy T, Acampora D, Araujo K, Charpentier P, Chattopadhyay S, Geda M, Gill T, Kaminski T, Lee S, Li J, Cohen A, Hajduk A, Ferrante L. In-Hospital Delirium and Disability and Cognitive Impairment After COVID-19 Hospitalization. JAMA Network Open 2024, 7: e2419640. PMID: 38954414, PMCID: PMC11220565, DOI: 10.1001/jamanetworkopen.2024.19640.Peer-Reviewed Original ResearchConceptsIn-hospital deliriumChart-Based Delirium Identification InstrumentOlder adultsFunctional disabilityCOVID-19 hospitalizationCognitive impairmentCohort studyAssociated with increased functional disabilityHospitalized older adultsIncreased functional disabilityAssociation of deliriumPostdischarge follow-upRisk of deliriumTertiary care systemFollow-upPresence of cognitive impairmentProspective cohort studyLogistic regression modelsOlder survivorsCare systemIncreasing cognitive impairmentMain OutcomesCOVID-19Hospital dischargePrimary outcomeAssociations of Social Support With Physical and Mental Health Symptom Burden After COVID-19 Hospitalization Among Older Adults
Lee S, McAvay G, Geda M, Chattopadhyay S, Acampora D, Araujo K, Charpentier P, Gill T, Hajduk A, Cohen A, Ferrante L. Associations of Social Support With Physical and Mental Health Symptom Burden After COVID-19 Hospitalization Among Older Adults. The Journals Of Gerontology Series A 2024, 79: glae092. PMID: 38558166, PMCID: PMC11059296, DOI: 10.1093/gerona/glae092.Peer-Reviewed Original ResearchConceptsLow social supportMental health symptomsSocial supportSymptom burdenHealth symptomsFollow-up assessmentCOVID-19 hospitalizationMedical Outcomes Study Social Support SurveyPhysical symptomsAssociation of social supportEdmonton Symptom Assessment SystemPatient Health Questionnaire-4Burden of physical symptomsMental health symptom burdenModified Edmonton Symptom Assessment SystemSocial Support SurveyParticipants' mean ageAssociated with higher burdenSupport SurveyOlder survivorsSymptom managementOlder AdultsMental healthHispanic ethnicityLongitudinal associationsUnraveling COVID-19 relationship with anxiety disorders and symptoms using genome-wide data
Asgel Z, Kouakou M, Koller D, Pathak G, Cabrera-Mendoza B, Polimanti R. Unraveling COVID-19 relationship with anxiety disorders and symptoms using genome-wide data. Journal Of Affective Disorders 2024, 352: 333-341. PMID: 38382819, DOI: 10.1016/j.jad.2024.02.061.Peer-Reviewed Original ResearchAnxiety disordersAnxiety symptomsAnxiety outcomesPeriods of anxietyCorrelates of anxiety disordersGenome-wide dataLocal genetic correlationLatent causal variable analysesBrain morphologyAnxietyGenetic correlationsCOVID-19 positive statusGenetic causality proportionDisordersPleiotropic mechanismsMillion Veteran ProgramVeteran ProgramSymptomsCOVID-19 hospitalizationCOVID-19 Host Genetics InitiativeComorbidityMultiple lociHost Genetics InitiativeCOVID-19 outcomesPositive status
2023
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, Philley J, Desruisseaux M, Keller M, Hochman J, Pirofski L, Ortigoza M, Hochman J, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Ortigoza M, Pirofski L, Yoon H, Sturm-Reganato C, Cobb G, Andela R, Darwish Y, Taveras M, Xin P, LaFleur J, Cleare L, Goldfeld K, Li Y, Ortigoza M, O'Keeffe M, Cobb G, Sturm-Reganato C, Rahman F, Ajayi A, Rodriguez S, Iturrate E, Gallagher J, Thomas O, Ramos D, Fong C, Pirofski L, Yoon H, Keller M, Asencio A, Eke I, Castro J, Shan J, Chalco A, LaFleur J, Cleare L, Desruisseaux M, Cortezzo G, Rocco E, Ndunge O, Parmelee C, Solomon G, Cahil S, Jayaweera D, Lee C, Ransford D, Dasmany D, Corona A, Moreno K, Martinez G, Otero C, McPherson D, Ostrosky-Zeichner L, Patel B, Nigo M, Huebinger R, Dronavalli G, Grimes C, Umana V, Hernandez M, Nielsen L, Stutz T, Mammadova M, Dentino A, Heath T, Martin J, Bello F, Hinojosa E, Philley J, Devine M, Hibbard R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases 2023, 11: ofad686. PMID: 38269049, PMCID: PMC10807994, DOI: 10.1093/ofid/ofad686.Peer-Reviewed Original ResearchPost-acute sequelaePROMIS scoresCOVID-19 convalescent plasma (CCP) therapySARS-CoV-2 infection symptomsSARS-CoV-2 infectionAcute COVID-19Convalescent plasma therapyGlobal health assessmentPhysical health scoresCOVID-19 hospitalizationCOVID-19 trialsSelf-reported symptomsRespective reference groupsRace/ethnicityPASC symptomsRandomization armAcute infectionAcute treatmentPlasma therapyGeneral symptomsSymptom SurveyLong-term effectsHealth scoresOverall healthDisease severityUncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks
Fritsche L, Nam K, Du J, Kundu R, Salvatore M, Shi X, Lee S, Burgess S, Mukherjee B. Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks. PLOS Genetics 2023, 19: e1010907. PMID: 38113267, PMCID: PMC10763941, DOI: 10.1371/journal.pgen.1010907.Peer-Reviewed Original ResearchConceptsPolygenic risk scoresMichigan Genomics InitiativeUK BiobankPre-existing conditionsPhenome-wide association studyAssociation studiesCohort-specific analysesPolygenic risk score approachUK Biobank cohortMeta-analysisIncreased risk of hospitalizationGenome-wide association studiesBody mass indexRisk of hospitalizationIdentified novel associationsRisk score approachCOVID-19 outcome dataCOVID-19 hospitalizationCOVID-19Mass indexRisk scoreBiobankCardiovascular conditionsCOVID-19 severityIncreased risk412. Comparison of Outcomes in Pneumonia Patients Hospitalized with COVID-19 and Influenza in Connecticut, 2015-2020
Kim D, Yousey-Hindes K. 412. Comparison of Outcomes in Pneumonia Patients Hospitalized with COVID-19 and Influenza in Connecticut, 2015-2020. Open Forum Infectious Diseases 2023, 10: ofad500.482. PMCID: PMC10679268, DOI: 10.1093/ofid/ofad500.482.Peer-Reviewed Original ResearchAcute respiratory distress syndromeAge groupsFluSurv-NETRespiratory failureMedian lengthDischarge diagnosisPneumonia casesChest X-ray/CTIntensive care unit admissionEmerging Infections ProgramAcute respiratory failureCare unit admissionLaboratory-confirmed influenzaChronic lung diseaseRespiratory distress syndromeLonger median lengthCoronavirus disease 2019 (COVID-19) pandemicLength of stayChronic metabolic diseaseComparison of outcomesCOVID-19 hospitalizationHospitalized COVID-19COVID-19Disease 2019 pandemicSame age groupImpact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network
Udelsman B, Detterbeck F, Tanoue L, Mase V, Boffa D, Blasberg J, Dhanasopon A, Ely S, Mazzarelli L, Bader A, Woodard G. Impact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network. Journal Of Computer Assisted Tomography 2023, 48: 222-225. PMID: 37832536, DOI: 10.1097/rct.0000000000001549.Peer-Reviewed Original ResearchHealth care networkLung cancer screening processLung cancer screening programsCare networkCancer screening programsCoronavirus disease 2019 (COVID-19) pandemicComputed tomography scanCOVID-19 hospitalizationCOVID-19 surgeCancer screening processDisease 2019 pandemicLung cancer diagnosisHealth care systemAverage hospitalizationRadiology databaseLung cancerTomography scanScreening programCare systemCancer diagnosisMonthsHospitalizationCOVID-19COVID-19 pandemicPandemicCOVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023
Taylor C, Patel K, Patton M, Reingold A, Kawasaki B, Meek J, Openo K, Ryan P, Falkowski A, Bye E, Plymesser K, Spina N, Tesini B, Moran N, Sutton M, Talbot H, George A, Havers F, Team C, Team C, Kirley P, Armistead I, Yousey-Hindes K, Oosmanally N, Monroe M, Henderson J, D’Heilly P, Hancock E, Barney G, Bushey S, Billing L, Abdullah N, Schaffner W, Mendez E. COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1089-1094. PMID: 37796744, PMCID: PMC10564325, DOI: 10.15585/mmwr.mm7240a3.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationCOVID-19-Associated Hospitalization Surveillance NetworkCOVID-19-associated hospitalization ratesHospitalization ratesAge groupsIntensive care unit admissionMultiple underlying conditionsSevere COVID-19 diseasePromote early treatmentPositive SARS-CoV-2 testSARS-CoV-2 infectionPrevent SARS-CoV-2 infectionYounger age groupsClinical characteristicsUnit admissionUnderlying conditionEarly treatmentSARS-CoV-2 testingIncreased riskSevere COVID-19-associated outcomesSevere outcomesCOVID-19 hospitalizationElevated riskCOVID-19 diseaseBivalent vaccineCOVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore
Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosCancer survivorsVaccine doseSevere diseaseCohort studyTreated patientsProspective multicenter observational cohort studyCompeting-risk regression analysisMulticenter observational cohort studyMatched controlsVaccine efficacyVaccine effectivenessRisk of poor outcomesWaning of vaccine effectivenessSevere COVID-19 disease outcomesMRNA vaccine doseRisk of deathObservational cohort studyMRNA-based vaccinesSocioeconomic statusSARS-CoV-2 DeltaRate ratiosCOVID-19 hospitalizationIncidence rateOmicron waveEvaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, Obeid W, Garibaldi B, Azeloglu E, Ugwuowo U, Sperati C, Arend L, Rosenberg A, Kaushal M, Jain S, Wilson F, Parikh C, Consortium T, Deng J, Atta M, Bagnasco S, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. American Journal Of Kidney Diseases 2023, 82: 322-332.e1. PMID: 37263570, PMCID: PMC10229201, DOI: 10.1053/j.ajkd.2023.03.010.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Major adverse kidney eventsAdverse kidney eventsAdverse kidney outcomesAcute kidney injuryKidney eventsTumor necrosis factor receptor 1Necrosis factor receptor 1Plasma biomarkersKidney outcomesC-indexFactor receptor 1Hospitalized patientsCOVID-19KDIGO stage 3 acute kidney injuryDialysis-requiring acute kidney injuryStage 3 acute kidney injuryLong-term adverse health outcomesReceptor 1Long-term kidney dysfunctionAvailable blood samplesIdentification of patientsProportional hazards regressionAdverse health outcomesCOVID-19 hospitalizationHuman Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, Horberg M, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clinical Infectious Diseases 2023, 76: 1727-1734. PMID: 36861341, PMCID: PMC10209434, DOI: 10.1093/cid/ciad084.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAdjusted risk ratioCOVID-19 hospitalizationMechanical ventilationTenofovir useHIV statusAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere coronavirus disease 2019 (COVID-19) outcomesSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) outcomesHuman immunodeficiency virus statusCohort of PWHCD4 cell countCharlson Comorbidity IndexCoronavirus 2 infectionHIV RNA levelsUnited States cohortBody mass indexCOVID-19 severityCOVID-19 vaccine availabilityReal-world analysisTenofovir exposureComorbidity indexMass index
2022
Rationale, Design, and Characteristics of the VALIANT (COVID‐19 in Older Adults: A Longitudinal Assessment) Cohort
Cohen A, McAvay G, Geda M, Chattopadhyay S, Lee S, Acampora D, Araujo K, Charpentier P, Gill T, Hajduk A, Ferrante L. Rationale, Design, and Characteristics of the VALIANT (COVID‐19 in Older Adults: A Longitudinal Assessment) Cohort. Journal Of The American Geriatrics Society 2022, 71: 832-844. PMID: 36544250, PMCID: PMC9877652, DOI: 10.1111/jgs.18146.Peer-Reviewed Original ResearchConceptsPatient-centered outcomesCOVID-19 hospitalizationCognitive impairmentPhysical functionOlder COVID-19 survivorsCOVID-19-related symptomsCOVID-19Older adultsIntensive care unitCOVID-19 survivorsPersistent cognitive impairmentSix-month followMost older adultsThird of participantsElectronic health recordsStepdown unitAcute illnessBurdensome symptomsCare unitSupplemental oxygenMedian lengthProspective studyMean ageBlack raceBaseline interviewTrends in disparities in COVID hospitalizations among community‐dwelling residents of two counties in Connecticut, before and after vaccine introduction, March 2020–September 2021
McWilliams C, Bothwell L, Yousey‐Hindes K, Hadler J. Trends in disparities in COVID hospitalizations among community‐dwelling residents of two counties in Connecticut, before and after vaccine introduction, March 2020–September 2021. Influenza And Other Respiratory Viruses 2022, 17: e13082. PMID: 36509459, PMCID: PMC9835416, DOI: 10.1111/irv.13082.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationNon-Hispanic blacksGeocoded residential addressesAge-adjusted incidenceNon-Hispanic whitesHispanic/LatinxVaccination ratesLaboratory-confirmed COVID-19Residential addressesSocioeconomic statusSurveillance Network databaseCommunity-dwelling residentsNon-institutionalized personsIntroduction of vaccinesLow socioeconomic statusCensus tract measuresRace/ethnicityLower SES groupsVaccine registryVaccine introductionVaccination levelsHospitalizationVaccine rolloutDelta wavesSES disparitiesA MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality
Verma A, Minnier J, Wan ES, Huffman JE, Gao L, Joseph J, Ho YL, Wu WC, Cho K, Gorman BR, Rajeevan N, Pyarajan S, Garcon H, Meigs JB, Sun YV, Reaven PD, McGeary JE, Suzuki A, Gelernter J, Lynch JA, Petersen JM, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Gatsby E, Lynch KE, Bonomo RA, Freiberg M, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Huang R, Polimanti R, Chang KM, Liao KP, Tsao PS, Wilson PWF, Hung A, O’Donnell C, Gaziano JM, Hauger RL, Iyengar S, Luoh SW, Initiative T. A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1220-1229. PMID: 35771531, PMCID: PMC9746845, DOI: 10.1164/rccm.202109-2166oc.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationIdiopathic pulmonary fibrosisMillion Veteran ProgramHost Genetics InitiativeAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionGene polymorphismsSyndrome coronavirus 2 infectionCoronavirus 2 infectionConfer protective effectsCOVID-19 positivityCoronavirus disease (COVID-19) infectionElectronic health recordsMVP subjectsPneumonia eventsClinical outcomesPulmonary fibrosisCOVID-19 Host Genetics InitiativeClinical eventsSevere outcomesProtective effectSevere diseaseRs35705950Disease severityMVP participantsLife stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization
Frontera J, Sabadia S, Yang D, de Havenon A, Yaghi S, Lewis A, Lord A, Melmed K, Thawani S, Balcer L, Wisniewski T, Galetta S, Agarwal S, Andino A, Arena V, Baskharoun S, Bauman K, Bell L, Berger S, Bhagat D, Bokhari M, Bondi S, Canizares M, Chervinsky A, Czeisler B, Dygert L, Fang T, Flusty B, Friedman D, Friedman D, Fuchs B, Granger A, Gratch D, Gurin L, Gutman J, Hasanaj L, Holmes M, Horng J, Huang J, Ishii H, Jauregui R, Ji Y, Kahn D, Koch E, Krieger P, Kvernland A, Lalchan R, Lillemoe K, Lin J, Liu S, Madhavan M, Medicherla C, Millar-Vernetti P, Morgan N, Olivera A, Omari M, Park G, Patel P, Ristic M, Rosenthal J, Sonson M, Snyder T, Stainman R, Sunwoo B, Talmasov D, Tamimi M, Thomas B, Valdes E, Zhou T, Zhu Y. Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. Journal Of The Neurological Sciences 2022, 443: 120487. PMID: 36379135, PMCID: PMC9637014, DOI: 10.1016/j.jns.2022.120487.Peer-Reviewed Original ResearchConceptsModified Rankin ScalePost-acute symptomsLong-term outcomesCOVID-19 hospitalizationBaseline disabilityBarthel IndexPoor outcomeFemale sexLife stressorsCOVID-19Telephone Montreal Cognitive AssessmentOlder ageMultivariable logistic regressionStrong independent predictorCOVID-19 patientsLongitudinal cohort studyCOVID-19 severityWorse mRSMontreal Cognitive AssessmentProlonged symptomsRankin ScaleCohort studyIndependent predictorsMultivariable analysisNeuropsychiatric outcomesThe first 20 months of the COVID-19 pandemic: Mortality, intubation and ICU rates among 104,590 patients hospitalized at 21 United States health systems
Fiore M, Smith S, Adsit R, Bolt D, Conner K, Bernstein S, Eng O, Lazuk D, Gonzalez A, Jorenby D, D’Angelo H, Kirsch J, Williams B, Nolan M, Hayes-Birchler T, Kent S, Kim H, Piasecki T, Slutske W, Lubanski S, Yu M, Suk Y, Cai Y, Kashyap N, Mathew J, McMahan G, Rolland B, Tindle H, Warren G, An L, Boyd A, Brunzell D, Carrillo V, Chen L, Davis J, Dilip D, Ellerbeck E, Iturrate E, Jose T, Khanna N, King A, Klass E, Newman M, Shoenbill K, Tong E, Tsoh J, Wilson K, Theobald W, Baker T. The first 20 months of the COVID-19 pandemic: Mortality, intubation and ICU rates among 104,590 patients hospitalized at 21 United States health systems. PLOS ONE 2022, 17: e0274571. PMID: 36170336, PMCID: PMC9518859, DOI: 10.1371/journal.pone.0274571.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsICU admission rateUnited States health systemState health systemAdmission ratesPositive COVID-19 PCR testCOVID-19 PCR testHospitalized COVID-19 patientsHealth systemHealth system contactElectronic health record dataICD-10 diagnosisAge 18 yearsCOVID-19 hospitalizationRisk-standardized mortalityHealth record dataHigh mortality rateCOVID-19 pandemicICU admissionHospitalized participantsEndotracheal intubationIntubation rateMean agePatient groupPatient outcomesSmoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study
Piasecki T, Smith S, Baker T, Slutske W, Adsit R, Bolt D, Conner K, Bernstein S, Eng O, Lazuk D, Gonzalez A, Jorenby D, D’Angelo H, Kirsch J, Williams B, Nolan M, Hayes-Birchler T, Kent S, Kim H, Lubanski S, Yu M, Suk Y, Cai Y, Kashyap N, Mathew J, McMahan G, Rolland B, Tindle H, Warren G, An L, Boyd A, Brunzell D, Carrillo V, Chen L, Davis J, Deshmukh V, Dilip D, Ellerbeck E, Goldstein A, Iturrate E, Jose T, Khanna N, King A, Klass E, Mermelstein R, Tong E, Tsoh J, Wilson K, Theobald W, Fiore M. Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study. Nicotine & Tobacco Research 2022, 25: 1184-1193. PMID: 36069915, PMCID: PMC9494410, DOI: 10.1093/ntr/ntac201.Peer-Reviewed Original ResearchConceptsNicotine replacement therapySARS-CoV-2 vaccinationCOVID-19 patientsCurrent smokersFormer smokersSmoking statusCOVID-19 outcomesICU admissionNRT prescriptionHospital outcomesVaccination statusReplacement therapySevere COVID-19 disease outcomesCOVID-19 clinical outcomesCOVID-19 disease outcomesBetter hospital outcomesOdds of deathBody mass indexElectronic health record dataLarge cohort studyCOVID-19 hospitalizationHealth record dataPotential beneficial effectsU.S. health systemEHR cohortUniversal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic
Galvani AP, Parpia AS, Pandey A, Sah P, Colón K, Friedman G, Campbell T, Kahn JG, Singer BH, Fitzpatrick MC. Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2200536119. PMID: 35696578, PMCID: PMC9231482, DOI: 10.1073/pnas.2200536119.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply